Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by educational grants from Clovis Oncology, Inc. and Myriad Genetics, Inc.
Salon Ballroom A 1 & 2, Lower Level
720 S. Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400
The treatment landscape for ovarian cancer has changed substantially with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitor therapy. It is important for clinicians who treat patients with ovarian cancer to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application. Other challenges associated with maximizing therapeutic outcomes with potential PARP inhibitor use include selection of optimal testing strategies to personalize care, management of treatment toxicities, and development of evidence-based sequencing and combination strategies.
This case-based educational activity, featuring leading experts in the treatment of patients with ovarian cancer, has been developed to help clinicians with the management of these challenges. Multiple topics pertaining to the use of PARP inhibitors in the treatment of ovarian cancers and other tumor targets will be explored through a combination of didactic presentation and panel discussion. The program will conclude with a question-and-answer session to allow participants to interact with the faculty to discuss challenges seen in their own practice settings.
This educational program is directed toward all attendees of the 2017 ASCO Annual Meeting, including medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of ovarian cancers and other emerging tumor targets. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with ovarian cancers also will be invited to participate.
Robert L. Coleman, MD, FACOG, FACS
Professor, Vice Chair of Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018